Clinical practice guidelines recommend that clinicians implement the 5As (Ask, Advise, Assess, Assist, and Arrange) for smoking cessation at every clinical encounter. 95% CI 0.3C0.8) or assessed for readiness to quit (AOR 0.6, 95% CI 0.4C0.9), patients with pulmonary diseases had higher odds of reporting being assisted (AOR 1.6, 95% 1.0C2.6) than patients without these diagnoses. Although the majority of clinicians reported asking (91.8%), advising (91.8%), and assessing (93.4%) tobacco use most of the time or always during a clinical encounter, fewer reported assisting (65.7%) or arranging (19.7%) follow-up. Only half of patients reported being screened for tobacco use and fewer reported receipt of the other 5As, with significant disparities in receipt of the 5As among patients with HIV. Our findings confirm the need for interventions to increase clinician-delivered cessation treatment in primary and HIV care. Keywords: Smoking cessation, AZ 3146 5As for smoking cessation, Primary care 1.?Introduction Tobacco use is the leading preventable cause of death, and is responsible for >?480,000 deaths annually in the United States (U.S.) (U.S. Department of Health and Human Services, 2014). The major causes of excess mortality among smokers stem from smoking-related cancers, cardiovascular disease and respiratory disease (Centers for Disease Control and Prevention, 2008a, Jha et al., 2013). Although the past 4 decades have seen significant declines in the prevalence of smoking in the general population, prevalence remains high among certain populations (Prevention CfDCa, 2014, Jamal et al., 2015). Low-income persons (Prevention CfDCa, 2014, Jamal et al., 2015), racial/ethnic minorities (Jamal et al., 2015, Centers for Disease Control and Prevention, 2005), persons with mental health disorders or substance use disorders (Schroeder and Morris, 2010), indigent persons living with HIV/AIDS (Vijayaraghavan et al., 2014), and persons who are uninsured or publicly insured (Centers for Disease Control and Prevention, n.d.), bear a disproportionate burden of tobacco-related morbidity and mortality (Centers for Disease Control and Prevention, 2008b). Primary care clinicians are in a unique position to help patients quit smoking by employing strategies outlined in the U.S. Public Health Service guidelines (Fiore et al., 2008). These guidelines recommend that all clinicians offer brief interventions for smoking cessation at all or nearly all encounters using the 5As (Ask about smoking, Advise cessation, Assess readiness to quit, Assist with motivation and/or cessation, and Arrange follow-up) (Fiore et al., 2008) Most smokers in the general population are interested in quitting smoking and almost half attempt to quit smoking yearly (Centers for Disease Control and Prevention, 2011). Smokers are receptive to counseling for smoking cessation (Fiore et al., 2008), and about half report having received advice to quit from a health professional (Centers for Disease Control and Prevention, 2011, Kruger et al., 2012). Most smokers cite clinician’s advice to quit smoking as an important motivator for smoking cessation (Kruger et al., 2012, Gilpin et al., 1993). Receipt of clinician-delivered counseling, in particular the more intensive Assist and Arrange interventions for smoking cessation has been shown to AZ 3146 increase cessation (Fiore et AZ 3146 al., 2008, Park et al., 2015). Receipt of all the 5As compared to one or none during a clinical encounter has been associated with increased use of cessation services (Kruger AZ 3146 et al., 2016). Despite patients’ interest in receiving counseling, there is significant variability in clinician delivery of the 5As (Park et al., 2015, Ferketich et al., 2006, Thorndike et al., 2007). Previous research has shown that while most smokers are screened for tobacco use, fewer are advised to quit or assessed for their readiness to quit, and only a minority report receipt of clinician-delivered Assist (pharmacotherapy and/or more intensive counseling) or Arrange (Park et al., 2015, Ferketich et al., 2006, Jamal et al., 2012). Fewer than 25% of Medicaid-enrolled smokers reported receiving assistance with cessation (Chase et al., 2007). Racial/ethnic minorities, persons of lower socioeconomic status, and younger persons are less likely to receive clinician-delivered cessation interventions (Danesh et al., 2014, Browning et al., Rabbit polyclonal to ITPKB 2008, Ferketich et al., 2014). Patient comorbidity and time spent with the physician are also associated with lower probability of receiving smoking cessation interventions in clinical care (Jamal et al., 2015, Ferketich et al., 2006, Silfen et al., 2015). In this study, we examined the prevalence of receipt of clinician-delivered 5As among patients in two diverse primary care clinics and one HIV care clinic and patient-related factors associated with receipt of the 5As. Consistent with previous studies (Park et al., 2015, Ferketich et al., 2006, Jamal et al., 2012), we hypothesized that receipt of Ask, Advise, and Assess would be higher than Assist and Arrange. We hypothesized that receipt of 5As would vary by clinic because of the distribution of patient comorbidity, and that patients with HIV/AIDS and those with mental health disorders or substance use.
Tag Archives: Keywords: Smoking cessation
Categories
- 34
- 5- Receptors
- A2A Receptors
- ACE
- Acetylcholinesterase
- Adenosine Deaminase
- Adenylyl Cyclase
- Adrenergic ??2 Receptors
- Alpha2 Adrenergic Receptors
- Annexin
- Antibiotics
- ATPase
- AXOR12 Receptor
- Ca2+ Ionophore
- Cannabinoid
- Cannabinoid (GPR55) Receptors
- CB2 Receptors
- CCK Receptors
- Cell Metabolism
- Cell Signaling
- Cholecystokinin2 Receptors
- CK1
- Corticotropin-Releasing Factor1 Receptors
- DHCR
- DMTases
- DNA Ligases
- DNA Methyltransferases
- Dopamine D1 Receptors
- Dopamine D3 Receptors
- Dopamine D4 Receptors
- Endothelin Receptors
- EP1-4 Receptors
- Epigenetics
- Exocytosis & Endocytosis
- Fatty Acid Synthase
- Flt Receptors
- GABAB Receptors
- GIP Receptor
- Glutamate (Kainate) Receptors
- Glutamate (Metabotropic) Group III Receptors
- Glutamate (NMDA) Receptors
- Glutamate Carboxypeptidase II
- Glycogen Phosphorylase
- Glycosyltransferase
- GnRH Receptors
- Heat Shock Protein 90
- hERG Channels
- Hormone-sensitive Lipase
- IKK
- Imidazoline Receptors
- IMPase
- Inositol Phosphatases
- Kisspeptin Receptor
- LTA4 Hydrolase
- M1 Receptors
- Matrixins
- Melastatin Receptors
- mGlu Group III Receptors
- mGlu5 Receptors
- Monoamine Oxidase
- Motilin Receptor
- My Blog
- Neutrophil Elastase
- Nicotinic (??4??2) Receptors
- NKCC Cotransporter
- NMU Receptors
- Nociceptin Receptors
- Non-Selective
- Non-selective 5-HT
- OP3 Receptors
- Opioid, ??-
- Orexin2 Receptors
- Other
- Other Oxygenases/Oxidases
- Other Transcription Factors
- p38 MAPK
- p53
- p56lck
- PAF Receptors
- PDPK1
- PKC
- PLA
- PPAR
- PPAR??
- Proteasome
- PTH Receptors
- Ras
- RNA Polymerase
- Serotonin (5-HT2B) Receptors
- Serotonin Transporters
- Sigma2 Receptors
- Sodium Channels
- Steroid Hormone Receptors
- Tachykinin NK1 Receptors
- Tachykinin NK2 Receptors
- Tachykinin, Non-Selective
- Telomerase
- Thyrotropin-Releasing Hormone Receptors
- Topoisomerase
- trpp
- Uncategorized
- USP
Recent Posts
- 2012) using the Phenotypic Characteristic Search for human strains with markers for resistance to Adamantane, Oseltamivir, or both drugs
- Tissue were homogenized into single-cell suspensions and put through red bloodstream cell lysis
- A phase I/II study investigated the safety and efficacy of concurrent local palliative RT and durvalumab (PD-L1 inhibitor) in 10 patients with unresectable or metastatic advanced solid tumors [136]
- We believe that this hypothesis-generating study could open new avenues for exploring oxidative stress as a potential pathogenetic and, hypothetically, therapeutic target for mitigating CLL strong class=”kwd-title” Keywords: Leukemia, Lymphocytic, Gilbert’s, Syndrome Gilbert’s syndrome (GS) is the most common inherited disorder of bilirubin glucuronidation
- Such costs aren’t simple for tertiary-care hospitals in growing countries sometimes, since these already are powered by minimal budget which switches into provision of fundamental medical services mostly, laboratory, radiology, pharmacy services, and bed space
Tags
a 67 kDa type I transmembrane glycoprotein present on myeloid progenitors
and differentiation. The protein kinase family is one of the largest families of proteins in eukaryotes
Apoptosis
bladder
brain
breast
cell cycle progression
cervix
CSP-B
Cyproterone acetate
EGFR) is the prototype member of the type 1 receptor tyrosine kinases. EGFR overexpression in tumors indicates poor prognosis and is observed in tumors of the head and neck
EM9
endometrium
erythrocytes
F3
Goat polyclonal to IgG H+L)
Goat polyclonal to IgG H+L)Biotin)
GRK4
GSK1904529A
Igf1
Mapkap1
monocytes andgranulocytes. CD33 is absent on lymphocytes
Mouse monoclonal to CD33.CT65 reacts with CD33 andtigen
Palomid 529
platelets
PTK) or serine/threonine
Rabbit Polyclonal to ARNT.
Rabbit polyclonal to BMPR2
Rabbit Polyclonal to CCBP2.
Rabbit Polyclonal to EDG4
Rabbit polyclonal to EIF4E.
Rabbit polyclonal to IL11RA
Rabbit polyclonal to LRRIQ3
Rabbit Polyclonal to MCM3 phospho-Thr722)
Rabbit Polyclonal to RBM34
SB 216763
SKI-606
SNX-5422
STK) kinase catalytic domains. Epidermal Growth factor receptor
stomach
stomach and in squamous cell carcinoma.
TNFSF8
TSHR
VEGFA
vulva